Last updated on December 2019

Safety and Efficacy Study of RP4010 in Patients With Relapsed or Refractory Lymphomas

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lymphoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Refractory to or relapsed after at least 1 prior treatment line.
  • Eastern Cooperative Oncology Group (ECOG) performance status 2
  • Patients must be 18 years of age
  • Able to give a written informed consent.

Exclusion Criteria:

  • Patients receiving cancer therapy within 3 weeks prior to Cycle1 Day1 (C1D1).
  • Patients with active Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immune deficiency virus (HIV) infection
  • Patients who received Allo-Stem cell Transplantation(Allo-SCT) within 12 months.
  • Patients with graft versus-host disease (GVHD)
  • Subjects who have received drugs that directly or indirectly inhibit calcineurin or Nuclear Factor of activated T cells (NFAT) activity .
  • Patient with symptomatic, or history of documented congestive heart failure (NY Heart Association functional classification III-IV);
  • Patient with Frederica's (QTcF) formulas (QTcF) 450 msec;
  • Patient with angina not well-controlled by medication;
  • Women who are pregnant or lactating.

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.